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A dilute-and-shoot flow-injection tandem mass spectrometry 
method for quantification of phenobarbital in urine
RATIONALE: Liquid chromatography/tandem mass spectrometry (LC/MS/MS) is the gold standard of urine drug 
testing. However, current LC-based methods are time consuming, limiting the throughput of MS-based testing and 
increasing the cost. This is particularly problematic for quantification of drugs such as phenobarbital, which is often 
analyzed in a separate run because they must be negatively ionized.
METHODS: This study examined the feasibility of using a dilute-and-shoot flow-injection method without LC separation 
to quantify drugs with phenobarbital as a model system. Briefly, a urine sample containing phenobarbital was first diluted 
by 10 times, followed by flow injection of the diluted sample to mass spectrometer. Quantification and detection of 
phenobarbital were achieved by an electrospray negative ionization MS/MS system operated in the multiple reaction 
monitoring (MRM) mode with the stable-isotope-labeled drug as internal standard.
RESULTS: The dilute-and-shoot flow-injection method developed was linear with a dynamic range of 50-2000 ng∕mL of 
phenobarbital and correlation coefficient > 0.9996. The coefficients of variation and relative errors for intra- and inter-
assays at four quality control (QC) levels (50, 125, 445 and 1600 ng∕mL) were 3.0% and 5.0%, respectively. The total 
run time to quantify one sample was 2 min, and the sensitivity and specificity of the method did not deteriorate even after 
1200 consecutive injections.
CONCLUSIONS: Our method can accurately and robustly quantify phenobarbital in urine without LC separation. Because 
of its 2 min run time, the method can process 720 samples per day. This feasibility study shows that the dilute-and-shoot 
flow-injection method can be a general way for fast analysis of drugs in urine. Copyright © 2016 John Wiley & Sons, Ltd.
Pain management drugs are among the most commonly 
prescribed drugs and yet also the most abused drugs.[1-4] 
Therefore, it has become a general medical practice to monitor 
patients who are taking pain management drugs, for 
adherence to treatment as well as to detect presence of other 
illicit substances and unprescribed drugs. The urine drug test 
(UDT) is the current clinical procedure for such patient 
monitoring, and there are millions of UDTs performed each 
year[5-8] Recently, liquid chromatography/tandem mass 
spectrometry (LC/MS/MS) has emerged as the gold standard 
UDT for quantification of pain management drugs in urine.
A routine UDT screening panel consists of more than 50 
commonly prescribed pain management drugs along with 
other abused molecules, among which only ethyl glucuronide 
(EtG, a metabolite biomarker for alcohol abuse) and 
barbiturates (commonly abused drugs) must be negatively 
ionized,[9-15] while the rest of them are positively ionized. 
Moreover, although both of them are negatively ionized, they 
must be analyzed in different LC runs because EtG is highly 
polar, while barbiturates are hydrophobic. Therefore, three 
separate LC/MS/MS runs[16-19] are generally carried out to 
identify/quantify the whole panel of pain management drugs
and illicit drugs in a routine clinical operation. This means that 
a single LC/MS/MS run operated in the positive ionization 
mode simultaneously analyzes the overwhelming majority of 
the drugs, and two additional separate LC/MS/MS runs are 
needed just to analyze EtG and barbiturates. The equipment 
needed for LC/MS/MS is expensive, requiring HPLC 
separation along with the MS/MS detection of drug molecules. 
Compared to MS∕MS, HPLC has a much longer run time to 
separate different molecules and reduce interferences, 
becoming the bottleneck of LC/MS/MS. Clearly, the general 
practice of running two separate LC/MS/MS runs just to 
analyze EtG and barbiturates greatly limits the throughput 
and increases the cost of a UDT. Hence, increasing the speed 
(throughput) of analyzing EtG and barbiturates is a major 
challenge faced by the clinical chemistry community.
As a part of our comprehensive effort to develop simple and 
rapid MS/MS-based methods for quantification of biomarkers 
in clinical specimens, we examined the feasibility of using the 
dilute-and-shoot flow-injection MS/MS (FI-MS/MS) method 
(without LC separation) for urine drug testing. In our method, 
a urine sample containing target drugs is spiked with internal 
standards, followed by enzymatic hydrolysis to cleave 
glucuronide conjugates.'20-22' The enzymatic treated sample 
is then diluted to minimize the matrix effect. Thereafter, the 
diluted sample is directly injected into the electrospray 
ionization (ESI) source of a tandem mass spectrometer 
operated in a MRM mode for identification and quantification. 
We hypotheses that this simple dilution along with selecting
good internal standards allows for fast, accurate and robust 
quantification of drugs in urine without pre-purification and 
LC separation.
In this study, we employed phenobarbital, the most 
prescribed barbiturate, as the model system to demonstrate 
the proof of principle. It was found that the dilute-shoot FI- 
MS/MS method developed was fast and robust for accurate 
quantification of phenobarbital in urine, where an 
autosampler directly introduces the sample along with the 
solvent into the mass spectrometer without a chromatographic 
column. The run time of our method is only 2 min long, 
enabling analysis of more than 720 urine samples per day, 
substantially increasing the throughput of MS-based UDT 
methods. To the best of our knowledge, this is the first report 
of accurate quantification of phenobarbital in urine by MS/MS 
without both pre-purification and LC separation. Reporting 
this study constitutes the focus of our communication.
EXPERIMENTAL
Materials and methods
Phenobarbital (analyte) and phenobarbital-D5 (internal 
standard, IS) were purchased from Cerilliant Corporation 
(Round Rock, TX, USA). B-Glucurodinase, Type-1, was 
obtained from Helix pomatia, and ammonium acetate were 
purchased from Sigma-Aldrich (Allentown, PA, USA). HPLC 
grade methanol and acetonitrile were purchased from 
Pharmco-Apper (Philadelphia, PA, USA). Deionized water 
was obtained from a Barnstead Nano pure water purification 
system from Thermo Scientific (Waltham, MA, USA). Drug- 
free urine was donated by six different healthy volunteers 
and was verified to not contain drugs before analysis.
Sample preparation
The urine drug samples used in this study were prepared by 
spiking phenobarbital and phenobarbital-D5 (IS) at the 
concentrations of 50, 100, 200, 500, 1000, and 2000 ng/mL 
and 500 ng∕mL (IS) respectively, in human blank urine. Each 
of the samples (100 μL) was then subjected to enzymatic 
hydrolysis by adding 200 units of β-glucurodinase and 
3 mM ammonium acetate buffer, vortexed, and then incubated 
at 55°C for 2 h. The hydrolyzed urine calibrators were diluted 
by ten times with deionized water and centrifuged at 13,000 g 
for 20 min. The supernatants were transferred into 
autosampler vials and analyzed using FI-MS/MS.
MS/MS instrumentation
Sample analysis was performed using 5500 QTRAP triple 
quadrupole mass spectrometer (AB Sciex, Toronto, Canada) 
with an electrospray ionization (ESI) source interfaced with 
a HPLC system containing two LC-30 AD pumps, a DUG- 
20A3R inline degasser, a SIL-30 AC autosampler, a CBM- 
20 A controller and a CTO-10AVP column oven (Shimadzu, 
Columbia, MD, USA).[23-25] It is noted that the HPLC system 
used herein was just for How-injecting samples into the ESI 
source and has no chromatography column connected. 
Ammonium acetate (5 mM) in 70% acetonitrile was employed 
as a carrier solvent at a flow rate of 0.3 mL∕min to inject the 
sample and the same solvent was used as a wash solvent,
which was done only after injecting samples with the highest 
concentration (2000 ng∕mL) in each batch. A volume of 10 μL 
of the sample was injected with a run time of 2 min per sample. 
All the MS and sample injection parameters were selected and 
controlled by Analyst software (version 1.5.2; AB Sciex, 
Toronto, Canada).
The ESI source and analyte-dependent MS parameters were 
optimized by a direct infusion of phenobarbital at 50 ng ∕mL in 
the negative ion mode. The parameters were selected based on 
a combination of high ion intensity, low noise background in 
urine matrix and reproducible analyte peak intensity. The 
MS parameters were as follows: (i) ESI source dependent 
parameters were optimized by direct infusion analysis: 
Curtain gas (35), nebulization gas (Gas I) (30), heating gas 
(Gas II) (30), ion spray voltage (-4000 eV), temperature 
(450°C). (ii) Analyte-dependent parameters were fine-tuned 
manually as follows: declustering potential (—110), entrance 
potential (—15), collision energy (—19), Cell exit potential 
(—15), dwell time for each multiple reaction monitoring 
(MRM) transition (150 ms).
Preparation of working solutions, calibrators, and quality 
control (QC) samples
Separate stock solutions of phenobarbital and phenobarbital- 
D5 (IS) were prepared at 50 μg∕mL and 10 μg∕mL from 
1 mg∕mL and 100 μg∕mL main stock solutions, respectively. 
The calibrators and QC samples were prepared from different 
sources of stock solutions. A set of phenobarbital working 
solutions of 50, 100, 200, 500, 1000, and 2000 ng/mL spiked 
with 500 ng∕mL phenobarbital-D5 (IS) were prepared by serial 
dilution from the stock solutions of phenobarbital and IS (in 
methanol), respectively. Similarly, the pooled urine calibrators 
(mixture of 6 lots of blank human urine) were prepared by 
spiking phenobarbital at 50-2000 ng/mL and 500 ng/mL IS 
followed by enzymatic hydrolysis and simple ten times 
(10×) dilution. Accuracy and precision measurements were 
assessed in QC samples at 50, 125, 445 and 1600 ng/mL, 
representing the lower limit of quantification (LLOQ), low 
QC (LQC), mid QC (MQC), and high QC (HQC) urine 
solutions, respectively. The working, QC and calibrators were 
then subjected to FI-MS/MS analysis. All the concentrations of 
phenobarbital reported are equivalent to the concentrations of 
phenobarbital in solvent without dilution.
RESULTS AND DISCUSSION
Method development
Optimization of flow injection mass spectrometric conditions for 
MRM quantitation
Because the dilute-and-shoot FI-MS/MS system has no LC 
column to separate the interfering background from the target 
drug and internal standard molecules, we first developed the 
conditions to minimize the effect of any potential interfering 
background on quantification. This was achieved by 
analyzing six different urine samples containing no 
phenobarbital under various conditions. Infusion experiments 
were performed to optimize MS/MS parameters, to select 
carrier solvent, buffers and fragment ions, and to produce 
strong signals of both the drug and IS. The negative ESI mode
was selected because phenobarbital is an acidic drug with a 
pH of 9-10, which carries a negative charge on the oxygen at 
position 4 of the barbiturate ring and thus can be more 
efficiently ionized in the negative ion mode. The internal 
standard (IS) used in this work was phenobarbital-D5. The 
use of deuterated drug molecules as internal standards can 
improve the quantitative accuracy, which is essential to 
dilute-and-shoot methods.[26-28]
Selection ofMRM transitions - phenobarbital and phenobarbital-D5
(IS) fragmentation
Fragmentation of precursor ions by collision-induced 
dissociation (CID), with a collision energy of 20 eV and the 
dwell time at 300 ms, led to the identification of product ions, 
with the transitions set at m/z 231.1 → 42.1 (quantitative) and 
m/z 231.1 → 188.1 (qualitative) for phenobarbital, and m/z 
234.2 → 85.1 for the IS (phenobarbital-D5), respectively. The 
fragmentation patterns are shown in Fig. 1. Under the 
conditions, the signal to noise was high, while the interference 
from other molecules was significantly reduced[29] It is noted 
that in this study, we have carefully evaluated the transitions 
m/z 231.1 → 188.1 and 231.1 → 42.1 in both the method 
development and validation phases. The transition m/z 
231.1 → 42.1 was selected as the quantitative channel due to 
its high signal intensity and better signal-to-noise ratio 
compared to m/z 231.1 → 188.1. The transition m/z 
231.1 → 188.1 was selected as a confirmation channel because
it is highly specific to phenobarbital. The fragment at m/z 42 
(NCO-) was derived via a retro-Diels-Alder reaction in CID, 
which is most commonly used for quantification of 
barbiturates.'30' The fragment at m/z 188.1 used as a 
confirmation channel was obtained by fragmentation at the 
N-C bond with a loss of a NCO- moiety. The fragment of m∕ 
z 85 (ONONH-), which was used as the quantification channel 
for the IS, was due to the fragmentation at the negative charge 
at O2 or O4 of the phenobarbital-D5 ring (IS). A quantitative 
channel is used to calculate the concentration based on the 
quantifier ion, while a qualitative channel is used to confirm 
the identification of the target analyte based on the ratio of 
the qualifier ion to quantifier ion.[27]
After optimization, we found that both the drug 
(phenobarbital) and the IS were well differentiated and that 
the background interference was minor, allowing for both 
the qualitative and quantitative determination of 
phenobarbital by MRM operated in the negative ionization 
mode. An isocratic flow of carrier solvent, 5 mM ammonium 
acetate in 70% acetonitrile at a flow rate of 0.3 mL∕min, was 
used to inject samples, as this solvent led to stronger signals 
for both phenobarbital and the IS and more effectively 
reduced the interference, compared with other solvents and 
buffers studied. The run time of our FI-MS/MS method 
was set for 2 min for each sample with a 10 μL injection 
volume. Under our optimized conditions, the peak with 
the strongest phenobarbital and IS signals was at 0.7 min 
after injection.
Figure 1. Precursor/product ion spectra and proposed fragmentation 
pathways for (A) phenobarbital and (B) internal standard phenobarbital-D5.
Phenobarbital cutoff concentration and calibration curve
In general, different predetermined cutoffs are used for 
different drugs, based on their distinct clinical significance. 
A too high cutoff can lead to false negatives, while false 
positives occur with a too low cutoff.[31,32] Based on clinical 
practice, a phenobarbital cutoff is generally set at 200 ng/mL 
(200 ng phenobarbital in 1 mL urine) by many reference 
laboratories.[27,33-35] With this in mind, we developed our 
calibration curve with the phenobarbital concentration 
ranging from 50 to 2000 ng/mL (Fig. 2), where the LLOQ 
(50 ng/mL) was set at 25% of the cutoff value (200 ng/mL 
phenobarbital). It is noted that the concentrations listed are 
the concentrations before 10× dilutions. Phenobarbital urine 
calibrators were prepared to obtain six urine calibrators: 
50 ng/mL, 100 ng/mL, 200 ng/mL (cutoff), 500 ng/mL, 
1000 ng∕mL and 2000 ng∕mL, where the cutoff concentration 
(200 ng∕mL) in urine falls in the mid-point of our linear range, 
enabling our method to determine the concentrations both 
higher and lower than the cutoff value in urine samples.
Analyte Conc. I IS 
Conc.
Figure 2. Calibration curve of phenobarbital in pooled blank 
human urine (mixture of 6 lots, 10× dilution). Linear 
regression (l /x weighting): y = 0.146x + —0.0278 (r = 0.9996).
Analytical method validation
A full method validation was performed for precision, 
accuracy, selectivity, lower limit of quantification (LLOQ), 
matrix effect and sample stability. The entire method was 
validated according to the currently accepted FDA 
Bioanalytical Method guidelines.[36]
Linearity, selectivity, sensitivity and LLOQ
The calibration plots were established using six phenobarbital 
urine calibrators at the concentrations of 50,100,200,500,1000, 
and 2000 ng∕mL, double blank and single blank (only IS). An 
excellent linearity was achieved with the mean correlation 
coefficient of r = 0.9996. Also, the calibration curves were 
evaluated by plotting standardized residual plots and checked 
for any outliers for each calibrator during the course of method 
validation for five batches on five separate days. The standard 
deviation (SD) for the residuals was found to be in the range of 
0.83-2.02, which is acceptable (< ±3 SD). The LLOQ and
selectivity of the method were assessed using the LLOQ 
(50 ng∕mL phenobarbital) and double blank urine samples 
from six different urine sources. Phenobarbital (Fig. 3) and IS 
peaks (Fig. 4) at LLOQ were obtained at ~0.7 min and no 
significant interferences were detected in these time windows 
in blank urine samples, showing the high selectivity of our 
method. The S/N ratio of the quantitative transition (42.1) 
and the qualitative transition (188.1) was 20 and 10 at LLOQ, 
respectively (Figs. 3 and 4). The coefficient of variation 
(%CV) and accuracy for the LLOQ were 1.4% and 3.5%, 
respectively, meeting the requirement of FDA guidelines 
(Table 1).
Precision, accuracy and matrix effect
To evaluate intra-day (within the same day) and inter-day (5 
different days) precision and accuracy, five replicates of three 
QC standards, LQC, MQC, and HQC of 125, 445 and 
1600 ng∕mL concentrations, along with the calibrators (50- 
2000 ng/mL) were analyzed within the same day and for 5 
consecutive days, respectively. The values for intra- and 
inter-day precision and accuracies ranged from 2.0 to 2.5% 
and 1.0 to 3.0%, and 1.98 to 3.78% and 1.47% to 4.19%, 
respectively, indicating that the FI-MS/MS method developed 
is highly precise and accurate with negligible deviations 
(Table 2).
Absolute and relative matrix effects were investigated in 
triplicate at three QC concentrations (125, 445 and 
1600 ng∕mL) in both pooled blank urine (mixture of 6 lots) 
and six individual urine lots. The absolute matrix effect was 
calculated by comparing the peak areas of diluted blank urine 
samples (10× dilution, both pooled and individual blank 
urine) spiked with phenobarbital at three QC concentrations 
with those of corresponding standard solutions at equivalent 
concentrations. The relative matrix effect was calculated by 
comparing the peak area ratio of phenobarbital and IS 
(phenobarbital-D5) spiked in the diluted blank urine samples 
at the same three QC concentrations with corresponding 
standard solutions at equivalent concentrations. The absolute 
matrix effect for each of the three QC pooled urine samples 
was 103.8%, 110.8%, and 112.8% and the relative matrix effect 
was found to be 98.7%, 108% and 110.5%, respectively 
(Table 3).
Similarly, absolute and relative matrix effect studies were 
performed in triplicate at three QC concentrations (125, 445 
and 1600 ng/mL) with six individual urine lots to determine 
the extent of variation of ion suppression among each lot. 
The absolute matrix effect for each lot at three QC 
concentrations ranged from 102.6 to 113.2% and the relative 
matrix effect ranged from 92.1 to 112.4%, respectively. The 
variability of the matrix effect among different urine samples 
was expressed as percent coefficient variation (%CV), where 
acceptable values <12% were obtained. These studies clearly 
show that the dilute-and-shoot technique for sample 
preparation was effective and had minimal matrix effects.
Sample stability studies
The stability studies (n = 3) were performed using two 
different QC standards (125 and 1600 ng/mL), which were 
exposed to the following regimens: 6 h at room temperature 
(bench-top stability), 2 months at —20oC, and 3 freeze/thaw
cycles within 3 days. The stability of phenobarbital and IS in 
human urine was evaluated after each storage period and 
compared to the freshly prepared samples of equivalent 
concentrations. The drug molecules were found to be stable 
and no loss or degradation of the analyte in urine was 
observed in all the studies (Table 4).
Figure 3. MRM extracted ion chromatograms (XICs) of (a) double blank pooled 
human urine (mixture of 6 lots, 10× dilution), (b) Blank pooled human urine 
(mixture of 6 lots, 10× dilution) spiked with phenobarbital at LLOQ level 
(50 ng/mL): Quantitative channel (42.0) and (c) Qualitative channel (188.0).
Figure 4. MRM extracted ion chromatograms (XICs) of (a) double blank pooled 
human urine (mixture of 6 lots, 10× dilution) and (b) single blank pooled human 
urine (mixture of 6 lots, 10× dilution) spiked with internal standard 
(phenobarbital-D5) (500 ng/mL).
Interference from other drugs
As described earlier, the current UDT typically detects two 
analytes in the negative ion mode. They are barbiturates and 
EtG. We have carried out a study to determine the effect of 
these molecules on the quantification of phenobarbital in
urine, where we spiked secobarbital, butalbital, pentobarbital 
and EtG into urine samples containing phenobarbital (LLOQ: 
50 ng∕mL, LQC: 125 ng∕mL, MQC: 445 ng∕mL, and HQC: 
1600 ng∕mL). This test was performed using both six separate 
lots of urine and one pooled lot (mixture of 6 individual lots). 
Our results showed that these molecules had no significant 
effects (either ion suppression or enhancement) on 
quantification of phenobarbital, suggesting that their presence 
is not a problem for quantifying phenobarbital for UDT.
Table 1. Accuracy and precision of phenobarbital 
calibration standards in pooled blank human urine




50 51.07 ±0.07 3.50 1.4
100 101.02 ± 0.21 1.20 2.1
200 190.88 ± 0.48 4.50 2.5
500 497.3 ± 0.88 1.27 1.8
1000 1009.0 ± 1.11 0.98 1.1
2000 2000.0 ± 0.54 0.10 0.7
Mixture of 6 lots, 10× dilution (n = 5) over 50-2000 ng/mL
Table 3. Absolute (AME) and relative matrix effect (RME) 
of phenobarbital in pooled blank human urine




50 108.5 ± 0.33 7 95.3 ± 0.33 6.9
125 103.8 ± 0.22 2 98.7 ± 0.22 2.1
445 110.8 ± 1.07 2 108 ± 1.07 1.9
1600 112.8 ± 2.56 2 110.5 ± 2.56 2
Table 4. Sample stability studies of phenobarbital in 










Freeze/thaw Low 125 126.0 ± 0.6 100.7
(3 cycles) High 1600 1587.3 ± 4.3 98.5
Bench top Low 125 125.2 ± 0.42 100.4
(6 h) at High 1600 1590.7 ± 5.43 99.4
room temp.
2 months at Low 125 127.3 ± 0.5 101.8
-20 oC High 1600 1597.2 ± 2.3 99.8
Mixture of 6 lots, 10× dilution (n = 3)
FI-MS/MS method with over 1200 consecutive injections 
during a 3-day period. It was found that the results were still 
reproducible even after 1200 injections, demonstrating that 
our method was robust enough for routine clinical operation.
CONCLUSIONS
We have successfully demonstrated the feasibility of using the 
dilute-an-shoot FI-MS/MS method for quantification of 
phenobarbital in urine. To the best of our knowledge, this is 
the first ESI-MS/MS study to quantify phenobarbital without 
LC separation. The method developed has the distinct 
advantage of being able to quantify and detect the presence 
of phenobarbital in urine even at 50 ng/mL. Importantly,
Table 2. Inter- and intra-assay accuracy and precision of phenobarbital in pooled blank human urine
Intra-assay Inter-assay
Spiked phenobarbital 
conc. (ng ∕ mL)
Measured 













Low QC 125 122.03 ± 0.22 2.5 2.13 122.32 ± 0.37 3.0 1.47
Mid QC 445 446.7 ± 1.07 2.0 3.78 446.88 ± 0.47 1.0 4.19
High QC 1600 1601.83 ± 2.56% 2.0 1.98 1598.83 ± 3.31 2.0 1.35
Mixture of 6 lots, 10× Dilution (n = 5)
Mixture of 6 lots, 10× Dilution (n = 3)
Evaluation of analytical performance and robustness of our 
FI-MS/MS method
Because our method does not use LC, it has a run time of only 
2 min. This means that with our method, the throughput of one 
MS/MS system can be as high as 720 samples per day, much 
higher than the throughout achieved by any LC/MS/MS 
method. Since the FI-MS/MS method developed is intended 
for clinical use, it must be reliable and robust. In other words, 
the performance of the method should not deteriorate after 
several hundreds of injections and results should be 
reproducible to avoid false positives and/or negatives, when 
implemented in clinical toxicology labs for routine UDTs. As 
demonstrated above, despite the presence of urine matrix, 
our FI-MS/MS method could still accurately quantify 
phenobarbital at 50 ng/mL (4 times lower than the cutoff 
currently used in clinical labs) and the signal intensity of both 
phenobarbital and IS was not compromised with the 
elimination of LC. The key to our FI-MS/MS method is the 
selection of proper fragmentation conditions and fragment 
channels so that the effect of the matrix background can be 
minimized. We have also tested the robustness of our
the method is ultra-fast and robust with simple dilution for 
sample pretreatment, short run time of 2 min, excluding HPLC 
separation. The validation study has shown that this method is 
accurate and precise, meeting the requirements of FDA 
guidelines. We present a proof-of-concept that the application 
of this method represents a robust, high-throughput and turn­
key analytical platform to address emerging concerns of 
analytical toxicological/clinical studies in urine. In spite of 
the single drug analysis in this study, the results are highly 
encouraging, and extending this approach to other drugs with 
similar ionization patterns will be highly beneficial. This 
method, an alternative approach to the current time- 
consuming LC/MS/MS method, meets the requirement of 
high-throughput UDT analysis with unparalleled speed. Its 
compelling analytical features and versatility offer a major 
improvement over existing methods. More importantly, the 
FI-MS/MS approach can be a general method for fast analysis 
of many other drug molecules present in clinical specimens. 
Finally, our method was developed as a model system only 
to test for the presence of phenobarbital in urine and the 
application of this method to quantify other drugs needs 
method validation for those drugs. Studies using this approach 
to quantify other drug molecules are in progress in our lab.
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